Immunotherapy boosts chemo to wipe out hidden leukemia cells
NCT ID NCT04214249
First seen Mar 20, 2026 · Last updated Jun 19, 2026 · Updated 11 times
Summary
This phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) achieve a deeper remission. About 49 participants will receive either chemo alone or chemo plus pembrolizumab. The main goal is to see if the combination can eliminate all traces of leukemia (minimal residual disease) better than chemo alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, New Hampshire, 03756, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
-
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298, United States
-
Wake Forest Baptist Health - Wilkes Medical Center
Wilkesboro, North Carolina, 28659, United States
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
-
Wake Forest University at Clemmons
Clemmons, North Carolina, 27012, United States
-
Yale University
New Haven, Connecticut, 06520, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (immunotherapy) plus standard chemotherapy (cytarabine and idarubicin or daunorubicin)
What this could lead to
If successful, this combination could help more people with AML achieve a deep remission with no detectable cancer cells left.
What could go wrong
This is a small, early-phase trial (49 people) and the added immunotherapy may cause immune-related side effects. It is not yet proven to improve long-term survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.